

1 **Effects of lidocaine on torn rotator cuff tendons**

2

3 Hirokazu Honda¹⁾, Masafumi Gotoh²⁾, Tomonoshin Kanazawa^{1),3)}, Hidehiro Nakamura¹⁾,

4 Keisuke Ohta³⁾, Kei-ichiro Nakamura³⁾, Naoto Shiba¹⁾

5 1) Department of Orthopedic Surgery, Kurume University, Fukuoka, Japan

6 2) Department of Orthopedic Surgery, Kurume University Medical Center, Fukuoka, Japan

7 3) Division of Microscopic and Developmental Anatomy, Department of Anatomy, Kurume
8 University school of Medicine, Fukuoka, Japan

9

10 **Running title:** Lidocaine affects rotator cuff tears

11

12 **Correspondence to:** Masafumi Gotoh, MD, PhD,

13 Department of Orthopedic Surgery, Kurume University Medical Center

14 155 Kokubu-machi, Kurume, Fukuoka 839-0863, Japan

15 Tel.: +81-942-22-6111 ex. 533; Fax: +81-942-22-6657

16 E-mail: gomasa@med.kurume-u.ac.jp

17 **Author Contributions:**

18 HH: Planned the study design, performed and analyzed histological data, and wrote the
19 manuscript

20 MG: Supervised the study design, analyzed data, and wrote the manuscript

21 TK, HN, KO, KN, NS: Supervised the study design and analyzed data

22 All authors have read and approved the final submitted manuscript.

23 The authors declare no conflicts of interest for this study.

24

25

26 **ABSTRACT**

27 We determined lidocaine's action on torn rotator cuff tendons *in vitro* and *in vivo*. For *in vitro*
28 experiments, cell proliferation and viability assays were performed using tenocytes derived from
29 human torn rotator cuff tendons. For *in vivo* experiments, acute rotator cuff tears were made on
30 the supraspinatus tendons in the rats' bilateral shoulders; before closure, lidocaine was injected
31 into the shoulder and saline into the contralateral shoulder (control). After sacrifice, the
32 specimens underwent biomechanical testing or histological analysis at 24 h and at 2, 4, and 8
33 weeks after surgery. The extent of collagen organization and apoptosis were semi-quantitatively
34 evaluated using collagen picrosirius red staining. Apoptosis was examined using TUNEL
35 staining and electron microscopy. Cell proliferation decreased dose-dependently. After exposure
36 to 0.1% lidocaine for 24 h, cell viability decreased. Two and 4 weeks after surgery, the ultimate
37 load to failure decreased more in the lidocaine group than in the control group, with significantly
38 reduced stiffness in the lidocaine group 2 weeks after surgery. Collagen organization

39 significantly decreased in the lidocaine group by 4 weeks after surgery but returned to baseline at
40 8 weeks. TUNEL staining detected numerous apoptotic tenocytes at the torn tendon edge
41 exposed to lidocaine 24 h after surgery; electron microscopy confirmed the condensed cell
42 nuclei. These changes were not observed in controls. Lidocaine caused cytotoxicity to tenocytes
43 under both conditions, decreased biomechanical properties, and induced apoptosis and delay of
44 collagen organization in this model. Subacromial lidocaine injections in patients with rotator cuff
45 tears should be performed carefully.

46

47 **Keywords:** lidocaine, rotator cuff, tendons, tenocytes

48 **Introduction**

49 Local anesthetics are clinically used for the treatment of tendinopathies. Peritendinous
50 injections of local anesthetics, in combination with other drugs (e.g., steroids), are given around
51 various joints to treat lateral and medial epicondylitis of the elbow, de Quervain’s disease,
52 patellar and pes anserine tendinopathies, and Achilles tendinopathy [1-6]. Similarly, subacromial
53 injections of anesthetic agents are used in rotator cuff tears as therapeutic and diagnostic tools
54 [7].

55 However, *in vitro* studies have shown the toxicity of local anesthetics on tendon
56 fibroblasts [8-11]. Lehner et al. reported that the treatment of rat tendon-derived cells with 0.5%
57 bupivacaine for 10 min had detrimental effects on cell viability [8]. Piper et al. showed a toxic
58 effect of 30 min of 1% lidocaine treatment on bovine tendon fibroblasts [9]. Yang et al.
59 concluded that lidocaine potentiated the deleterious effects of triamcinolone acetonide on
60 cultured tenocytes derived from rat-patellar tendons [10]. Recently, Sung et al. compared the
61 cytotoxic effects of ropivacaine, bupivacaine, and lidocaine on human rotator cuff tendon
62 fibroblasts and showed high cytotoxicity of lidocaine compared with the other agents, even in
63 low concentration [11].

64 Despite the deleterious effects of the local anesthetics as evaluated by *in vitro* studies [8-
65 11], lidocaine is frequently used preoperatively in clinical practice in rotator cuff tears [12-15];

66 however, *in vivo* data on the effects of lidocaine are lacking. These results prompted us to
67 examine how lidocaine acts on rotator cuff tears when used in subacromial injection for this
68 disease. Thus, the purpose of the present study was to evaluate the effects of lidocaine on
69 cultured tenocytes from human rotator cuff tendons in an animal cuff tear model. We
70 hypothesized that lidocaine has deleterious effects on tenocytes *in vitro* and *in vivo*.

71

72 **Methods**

73 Lidocaine was purchased from Maruishi (1% lidocaine injection; Osaka, Japan).
74 Dulbecco's modified Eagle's medium (DMEM) and L-glutamine were purchased from Nissui
75 Seiyaku (Tokyo, Japan), and fetal bovine serum (FBS) was purchased from Thermo Scientific
76 (Tokyo, Japan).

77

78 **Study Design**

79 All applicable international, national, and our institutional guidelines for the care and
80 use of animals and Ethics Committee were followed. Informed consent was obtained from all
81 individual participants included in the study. All tests and measurements were performed blindly.

82

83 For the *in vitro* experiments, the tenocytes obtained from torn human rotator cuff

84 tendons were cultured in monolayers at various concentrations of lidocaine (0.001%, 0.01%,
85 0.05%, and 0.1%); 9 specimens were used in the cell-proliferation assay, and 5 specimens were
86 used in the cell-viability assay. A singlicate analysis was performed to collect experiment data.

87 For the cell-proliferation assay, cultured cells from a specimen were divided into 5
88 groups and exposed to 5 graded concentrations of lidocaine (control, 0.001%, 0.01%, 0.05%, and
89 0.1%). Therefore, 9 data points were obtained in total. For the cell-viability assay, cultured cells
90 from a specimen were divided into 2 groups and exposed to either 0% or 1% lidocaine.
91 Therefore, 5 data points were obtained in total.

92 For the *in vivo* experiments, adult Sprague–Dawley rats (n = 33) underwent bilateral
93 shoulder surgery, and a total of 66 shoulders were assessed. The shoulders were allocated into 2
94 groups: lidocaine and control. Each group consisted of 6 specimens for biomechanical testing
95 and 3 for histological analysis and was evaluated 2, 4, and 8 weeks after surgery. Six specimens
96 in each group were subjected to 3 TUNEL staining and 3 electron microscopy analyses 24 h after
97 surgery (Figure 1).

98

99 **Tissue preparation**

100 Fourteen patients (9 males, 5 females) with rotator cuff disease were included in this
101 study. Nine subjects had right shoulder involvement, and 5 subjects had left shoulder

102 involvement. There were 2 small, 5 middle, 3 large, and 4 massive tears. Average subject age
103 was 62.4 ± 9.6 years, and the average period from symptom onset was 69.7 ± 73.8 weeks. All the
104 patients had received subacromial injections of a steroid or hyaluronic acid in addition to
105 physical therapy. Arthroscopic cuff repair was performed for a minimum of 2 months after the
106 last subacromial injection to minimize any potential effects of the agents.

107 The specimensSpecimens of the rotator cuff tendon were 3–5 mm in width and were
108 obtained from the margins of human rotator cuff tendons. The biopsy was performed in the
109 supraspinatus tendon and partly in the infraspinatus tendon when the tear size was large or
110 massive. Care was taken not to contaminate other types of adjacent tissue (muscle or synovium).
111 The cuff tear was completely repaired without excessive tension at the sides.

112

113 **Tenocytes Culture**

114 Torn human rotator cuff tendons were obtained from 14 patients during surgery, and
115 explant cultures were performed to isolate tenocytes. The tissues were rinsed twice in phosphate-
116 buffered saline (PBS) and cut into small pieces, and the tenocytes were maintained in culture
117 medium consisting of high-glucose DMEM (Nissui, Tokyo, Japan), 10% FBS (Thermo
118 Scientific, Utah, USA), and 1% penicillin/streptomycin (Nacalai Tesque, Kyoto, Japan) in an
119 incubator at 37°C with 5% CO₂. The culture medium was changed twice a week. The tenocytes

120 from the second passage were used for the experiments.

121

122 **Cell Proliferation Assay**

123 Cultured human tenocytes were seeded onto 96-well plates at a density of 5,000
124 cells/well and incubated with DMEM containing 10% FBS for 24 h. The tenocytes were treated
125 with lidocaine (Maruishi, Osaka, Japan) at various concentrations (0.001%, 0.01%, 0.05%, and
126 0.1%) for the next 24 h. After a 3-h reaction with WST-8 cell count reagent (Nacalai Tesque), the
127 fluorescence intensity of each well was measured using a microplate reader (BIO-RAD Model
128 550; Bio-Rad Laboratories, Richmond, CA, USA) at a wavelength of 450 nm.

129

130 **Cell Viability Assay**

131 Cultured human tenocytes were seeded onto 6-well plates at a density of 1.5×10^5
132 cells/well and incubated with DMEM containing 10% FBS for 24 h. The cells were exposed to
133 0.1% lidocaine or only to medium (controls) for the next 24 h. Floating cells and trypsinized
134 adherent cells were combined and diluted to 1×10^6 cells/ml with 1X PBS. The components of a
135 LIVE/DEAD Cell Viability Assay Kit (Invitrogen, OR, USA), C12-Resazurin, and SYTOX
136 GREEN were applied to stain viable and dead cells. After incubation for 15 min at 37°C, the
137 numbers of viable and dead cells were obtained by using a FACS instrument (BD Bioscience,

138 USA).

139

140

141 **Rotator Cuff Tear Model in Rats**

142 Thirty-three adult Sprague–Dawley male rats (mean body weight, 487.4 ± 93.2 g) were

143 used according to the guidelines of the Institutional Animal Care and Use Committee. Animals

144 were anesthetized with isoflurane under a high flow rate of oxygen. A middle skin incision was

145 made and subcutaneous tissue was divided. After the deltoid was divided to expose the

146 subacromial space, a complete tear was made on the supraspinatus (SSp) tendon with a #11

147 scalpel blade. The supraspinatus tendon was totally resected with preservation of its cartilaginous

148 portion and adjacent tendons (the infraspinatus and subscapularis tendons). Then, the

149 myotendinous unit was immediately retracted (Figures 2a, b). Before skin closure, 0.1 μ l (1%

150 lidocaine)/body weight (g), dose used in the rat is equal to 0.1 ml/1% lidocaine/body weight (kg)

151 in humans, was injected onto the tendon around the deficit site, and PBS was injected onto the

152 contralateral shoulder as a control. The animals were allowed to move freely in their cages after

153 surgery.

154

155 **Biomechanical Testing**

156 All specimens were immediately tested after sacrifice. Soft tissues were removed except
157 for the SSp tendon–humerus complex. Each specimen was then placed into a uniaxial testing
158 machine (TENSILON RTE-1210; Orientec, USA). The SSp tendon was secured in a screw grip
159 by using sandpaper and ethyl cyanoacrylate, and the humerus was secured in a custom-designed
160 pod by using a capping compound. The SSp tendon–humerus complex was positioned to allow
161 the tensile loading in the longitudinal direction of the injured site for the SSp tendon (Figure 2b).
162 The specimens were preloaded at 0.1 N for 5 min, followed by 5 cycles of loading and unloading
163 with 0.5 N at a cross-head speed of 5 mm/min and then loaded until failure at 1 mm/min. The
164 ultimate load to failure and linear stiffness were calculated from the resulting load-elongation
165 curve. This testing protocol was similar to that described previously [16, 17].

166

167 **Hematoxylin and Eosin (HE), Picrosirius Red, and Terminal Deoxynucleotidyl Transferase**
168 **dUTP-mediated Nick End-labeling (TUNEL) Staining**

169 The SSp tendon–humerus complex was fixed in 10% buffered formalin and then
170 decalcified with formic acid solution. Tissues were processed for paraffin embedding.
171 Longitudinal sections of 5- μ m thickness of the SSp tendon–bone complex were placed on the
172 glass slides and stained with either HE or picrosirius red. The specimens were visualized under a
173 light and polarized light microscope (OLYMPUS BX50; OLYMPUS, Tokyo Japan), and

174 photomicrographs were obtained using an Olympus DP71 digital camera (Olympus).

175

176 Picrosirius red staining was used for the evaluations of the collagen organization [17-
177 20]. For the semi-quantitative analysis, 2 of 3 glass slides were randomly selected from each
178 group, and photomicrographs were taken at 100× magnification. Consequently, a total of 36
179 photomicrographs were digitized (8-bit) using ImageJ software at a resolution of 1360 × 1024
180 pixels. In each photomicrograph, 10 randomly selected areas (50 μm × 50 μm) were evaluated by
181 measuring the degree of gray scale on the area, yielding an image in which non-collagenous
182 tissue was dark, and collagen was depicted on the gray scale of 1–255. Finally, the average
183 values of 10 areas in each specimen were calculated; higher values indicated more organized
184 collagen. This testing protocol was similar to that described previously [19, 20].

185 To evaluate apoptosis at the torn site, tendon specimens were subjected to TUNEL
186 staining 24 h after surgery using an *in situ* cell death kit (WAKO Chemical, Japan) according to
187 the manufacturer's instructions. DNase-digested sections served as a positive control, and TdT
188 (–) sections served as a negative control.

189

190 **Ultrastructure Analysis by Low-Voltage Scanning Electron Microscopy (LV-SEM)**

191 Tenocyte morphology was analyzed 24 h after surgery using wide-range observation of
192 the flat block face by LV-SEM.

193 Sprague–Dawley rats were deeply anesthetized, transcardially perfused through the left
194 ventricle with heparin-containing saline, and subsequently fixed with half Karnovsky’s solution
195 (2% paraformaldehyde, 2.5% glutaraldehyde, and 2 mM CaCl₂ in 0.1 M cacodylate buffer). After
196 perfusion, the SSp tendon–humerus complex was harvested and immersed in the same fixative
197 for 2 h at 4°C. After decalcification with Kalkitox solution (WAKO Chemical), the specimens
198 were cut into small cubes and fixed with ferrocyanate and 1% OsO₄, treated with 1%
199 thiocarbohydrazide, and then immersed in 1% OsO₄. For en bloc staining, the specimens were
200 immersed overnight in a solution of 4% uranyl acetate and washed with distilled water. Next, the
201 specimens were stained with Walton’s lead aspartate solution, dehydrated with a graded ethanol
202 series, infiltrated with an epoxy resin mixture, and polymerized at 60°C for 72 h. The resin
203 blocks containing the entire surgical site were trimmed to 2 mm × 4 mm in size, and the surfaces
204 of the embedded specimens were exposed using a diamond knife. Ultrastructural
205 photomicrographs of various regions at the surgical sites, as material contrast images resembling
206 transmission electron microscopy images referred to as block face images [19], were obtained
207 from the block surface of the same specimen using LV-SEM. The images were obtained under
208 the following conditions: accelerating voltage = 2 kV, dwell time = 30 μ seconds, and image size

209 = 2048 × 1768.

210

211 **Statistical Analysis**

212 Statistical analysis was performed by using JMP version 11 (SAS Institute Inc., Cary,
213 NC, USA). Kruskal–Wallis test with the Wilcoxon test as a *post-hoc* analysis was used to
214 evaluate lidocaine and control groups by comparing cell proliferation and viability. Two-way
215 ANOVA test of variance with the Wilcoxon test as a *post-hoc* analysis was used to evaluate
216 biomechanical data and picosirius red staining (gray scale). Values were shown as mean ±
217 standard deviation (SD). Differences with a *P* value <0.05 were considered to be significant.

218

219 **Results**

220 **Cell Proliferation**

221 When the values in the control group were defined as 100%, the relative ratio
222 (lidocaine/control) was 97.7% for 0.001% lidocaine, 95.6% for 0.01% lidocaine, 85.2% for
223 0.05% lidocaine, and 68.2% for 0.1% lidocaine (Figure 3a). Thus, lidocaine significantly
224 decreased cell proliferation of the cultured human tenocytes in a dose-dependent manner (*P* <
225 0.05).

226

227 **Cell Viability**

228 Under exposure to 0.1% lidocaine for 24 h, the FACS quantification analysis showed
229 significantly decreased cell viability in the lidocaine groups (% live cells, 75.0 ± 7.0) relative to
230 that in the control groups (% live cells: 86.9 ± 8.0) (Figure 3b).

231

232 **Biomechanical Strength**

233 All specimens tested failed at the site of the SSp tendon tear. The ultimate load to failure
234 values (lidocaine vs. control group) were 11.5 ± 3.5 N and 21.4 ± 2.5 N at 2 weeks after surgery
235 ($P < 0.05$), 17.5 ± 3.1 N and 22.2 ± 2.1 N at 4 weeks after surgery ($P < 0.05$), and 23.3 ± 4.0 N
236 and 29.8 ± 8.1 N ($P = 0.13$) at 8 weeks after surgery (Figure 4a). Thus, significant differences
237 between the 2 groups were noted at 2 and 4 weeks after surgery.

238 The stiffness values (lidocaine vs. control group) were as follows: 9.9 ± 6.1 N/mm and
239 19.6 ± 6.3 N/mm at 2 weeks after surgery ($P < 0.05$), 15.5 ± 4.0 N and 18.0 ± 2.6 N at 4 weeks
240 after surgery ($P = 0.3$), and 27.1 ± 8.2 N and 30.8 ± 12.1 N at 8 weeks after surgery ($P = 0.42$)
241 (Figure 4b). Thus, significant differences between the 2 groups were noted only at 2 weeks after
242 surgery.

243

244 **Evaluation of Fibrovascular Tissue at the Torn Site**

245 Two weeks after surgery, the abundant fibro-vascular tissue from the extra-articular side
246 encroached on the torn tendons in both groups. Compared with the control group, the thickness
247 of the fibro-vascular tissue was relatively lesser in the lidocaine group, with irregular collagen
248 bundles and less cellularity. These changes continued till 4 weeks after surgery, but no apparent
249 difference was seen 8 weeks after surgery.

250

251 **Evaluation of the Collagen Organization at the Torn Site**

252 Extent of the collagen organization at the torn site (lidocaine vs. control) was
253 significantly lesser in the lidocaine group: the gray scale values were 32.0 ± 19.0 and 49.9 ± 27.9
254 at 2 weeks after surgery ($P < 0.05$) and 41.0 ± 15.1 and 57.7 ± 22.9 at 4 weeks after surgery ($P <$
255 0.05); however, there was no significant difference in the values at 8 weeks after surgery
256 (lidocaine vs. control: gray scale values of 66.3 ± 25.5 and 68.4 ± 27.4) ($P = 0.82$) (Figures 5a,
257 5b, 5c).

258

259 **Apoptotic Cells at the Torn Site**

260 In the tendon specimens 24 h after surgery, a large number of TUNEL-positive cells
261 were observed in the lidocaine group (Figure 6a) but not in the control group (Figure 6b).

262

263 **Apoptotic Cells at the Torn Site Evaluated at the Ultrastructural Level**

264 In the tendon specimens 24 h after surgery, segmentalized collagen fibrils and
265 condensed nuclei of the tenocytes were observed at the edge of the torn tendon where lidocaine
266 was directly injected (Figure 7a). In contrast, these findings were not evident in the control
267 group. (Figure 7b)

268

269 **Discussion**

270 The delayed organization of collagen fiber in the rat rotator cuff tear model used in this
271 study showed that lidocaine significantly inhibited cell proliferation and caused cell death in
272 tenocytes from torn human rotator cuff and that lidocaine induced apoptosis, collagen necrosis,
273 and decreased biomechanical strength at the tear site. Thus, this study showed that lidocaine
274 caused adverse effects on tenocytes in torn rotator cuff tendons.

275 *In vitro* studies [21-24] have demonstrated considerable local anesthetic toxicity on
276 various cell types, including tendon fibroblasts derived from bovine tendon [3] and torn human
277 rotator cuff tendons [5]. Recently, an *in vitro* study revealed the cytotoxic mechanism of
278 aminoamide local anesthetics acting on human rotator cuff tendon fibroblasts [5]. That study
279 evaluated the response of tendon fibroblasts to ropivacaine, bupivacaine, and lidocaine and found
280 that these anesthetics caused cell death that was mediated by increased production of reactive

281 oxygen species. The reactive oxygen species resulted from increased activation of extracellular
282 signal-regulated kinase 1/2, c-Jun N-terminal kinase, and p38 and by activation of caspase-3/7
283 [5]. Similarly, the *in vitro* experiments in the present study showed cytotoxic effects of lidocaine
284 on the tenocytes derived from human rotator cuff tendons.

285 Regarding the *in vivo* effects of local anesthetics on tendons, only a few reports have
286 addressed this topic. Lehner et al. showed that 0.5% bupivacaine elicited a temporary functional
287 damage after a single peritendinous injection on rat Achilles tendon and demonstrated cell
288 apoptosis at the injection site [2]. Friel et al. evaluated the effect of continuous subacromial
289 0.25% bupivacaine infusion on repaired SSp tendons in a rabbit rotator cuff repair model, and no
290 significant differences in the biomechanical and histological features were found between the
291 bupivacaine-treated and control groups [25]. In our rat cuff tear model, a single injection of 1.0%
292 lidocaine caused apoptotic changes in tenocytes 24 h after surgery and delayed organization at
293 the tear site by 4 weeks after surgery. These discrepancies appear to be either related to
294 differences in the animal models or the concentrations of local anesthetics used in these studies.

295 Unlike the “cuff tear” model in the present study or the “peritendinous injection” model
296 reported by Lehner et al. [2], a “tear and subsequent repair” model [26,27] may not have
297 predisposed tenocytes to be exposed at sufficient levels of concentration because the cells are
298 protected/covered by tendon repair. In contrast, the “cuff tear” model in the present study may

299 have caused relatively high-concentration exposure to the tenocytes, and this may also have
300 occurred in the “peritendinous injection” model [2], in which the agents were potentially injected
301 into the tendinous portion. Previous *in vitro* studies have demonstrated that local anesthetics
302 inhibited cell proliferation and/or viability in a dose-dependent manner [4,23,28]. Thus, the
303 milieu of the injection site seems to directly determine the effects of local anesthetics; in fact, in
304 the present study, the tenocytes at the edge of the tear site that were directly exposed to lidocaine,
305 but not the cells exposed to PBS (control), underwent apoptotic changes.

306 We previously demonstrated the healing capability of torn tendon edges in patients with
307 rotator cuff tears by detecting procollagen types I and III gene expression in the tendon
308 fibroblasts [29-32]. These procollagen gene expression levels at the edge of the torn tendon
309 significantly correlated with re-tear after surgery [29]. In the present study, significant decrease
310 in the ultimate load to failure and delay of collagen organization in the lidocaine group continued
311 at 4 weeks after surgery. In a randomized, double-blind, prospective study, the accuracies of
312 landmark- and ultrasound-guided injections were 70% and 65%, respectively, for subacromial
313 space ($P < 0.05$) [33-34]. Taking these into considerations, lidocaine administration into the
314 subacromial space may affect the tenocytes when directly injected into the tendon mid-
315 substance; therefore, careful administration of lidocaine is necessary before operation.

316

317 **Limitations**

318 There were some limitations in this study. First, an acute rotator cuff tear rat model was
319 used, which is not applicable to humans with chronic tendinopathy; hence, caution is required
320 when applying the results from the rat model to human clinical situations. Second, the spectrum
321 of the lidocaine concentrations evaluated was narrow. The stumps of human rotator cuff tears are
322 usually covered by fibrin [35]; therefore, the cells may not be exposed to the same concentrations
323 as used in the present study as long as the lidocaine is not injected intratendinously. Third, the
324 influence of lidocaine combined with steroids that are frequently used in subacromial injections
325 was not examined. Fourth, cultured cells from uninjured tendons were used in the present study,
326 which may have had much greater variability similar to the variability in the clinical
327 presentation. Fifth, the present study was an observational study because the pathway
328 mechanisms were not examined. Sixth, the possibility of a phenotype change could not be
329 completely excluded because the cells behaved differently once they dissociated from their
330 native extracellular matrix. Seventh, we evaluated load and stiffness but not material properties
331 (e.g., stress, modulus), which may add significant uncertainty to the interpretation of findings.
332 Eighth, the sample size in this study was small, which may have caused a type II statistical error.
333 Resolution of these issues would add clarity to our study findings.

334

335 **Conclusions**

336 This study showed that lidocaine caused cytotoxicity to the tendon fibroblasts *in vitro*
337 and decreased the biomechanical properties in a rat rotator cuff tear model, inducing apoptosis
338 and delaying collagen organization at the tear site. The effect of significant decrease in
339 biomechanical strength with delayed tissue reorganization continued at 4 weeks after surgery;
340 thereafter, biomechanical strength with delayed tissue reorganization returned to baseline levels
341 by 8 weeks after surgery. Although the rat model used in the present study may not be fully
342 representative of clinical settings, we think that subacromial lidocaine injections in patients with
343 rotator cuff tears should be carefully administered before operations.

344

345

346 **Acknowledgments:**

347 We would like to express our gratitude and appreciation to Ms. Marina Sakata for her technical
348 assistance.

349

350 **References**

- 351 1. Toker S, Kiliçoğlu V, Aksakalli E, et al. 2008. Short-term results of treatment of tennis
352 elbow with anti-inflammatory drugs alone or in combination with local injection of a
353 corticosteroid and anesthetic mixture. *Acta Orthop Traumatol Turc* 42: 184–187. [Article in
354 Turkish]
- 355
- 356 2. Hashiuchi T, Sakurai G, Morimoto M, et al. 2011. Accuracy of the biceps tendon sheath
357 injection: ultrasound-guided or unguided injection? A randomized controlled trial. *J Shoulder*
358 *Elbow Surg* 20: 1069–1073.
- 359
- 360 3. Jeyapalan K, Choudhary S. 2009. Ultrasound-guided injection of triamcinolone and
361 bupivacaine in the management of De Quervain's disease. *Skeletal Radiol* 38: 1099–1103.
- 362
- 363 4. Hart L. 2011. Corticosteroid and other injections in the management of tendinopathies: a
364 review. *Clin J Sport Med* 21: 540–541.
- 365

- 366 5. Crisp T, Khan F, Padhiar N, et al. 2008. High volume ultrasound guided injections at the
367 interface between the patellar tendon and Hoffa's body are effective in chronic patellar
368 tendinopathy: A pilot study. *Disabil Rehabil* 30: 1625–1634.
- 369
- 370 6. Chan O, O'Dowd D, Padhiar N, et al. 2008. High volume image guided injections in chronic
371 Achilles tendinopathy. *Disabil Rehabil* 30: 1697–1708.
- 372
- 373 7. Farshad M, Jundt-Ecker M, Sutter R, et al. 2012. Does subacromial injection of a local
374 anesthetic influence strength in healthy shoulders?: a double-blinded, placebo-controlled study. *J*
375 *Bone Joint Surg Am* 94: 1751–1755.
- 376
- 377 8. Lehner C, Gehwolf R, Hirzinger C, et al. 2013. Bupivacaine induces short-term alterations and
378 impairment in rat tendons. *Am J Sports Med* 41: 1411–1418.
- 379
- 380 9. Piper SL, Laron D, Manzano G, et al. 2012. A comparison of lidocaine, ropivacaine and
381 dexamethasone toxicity on bovine tenocytes in culture. *J Bone Joint Surg Br* 94: 856–862.
- 382
- 383 10. Yang SL, Zhang YB, Jiang ZT, et al. 2014. Lidocaine potentiates the deleterious effects of

384 triamcinolone acetonide on tenocytes. *Med Sci Monit* 20: 2478–2483.

385

386 11. Sung CM, Hah YS, Kim JS, et al. 2014. Cytotoxic effects of ropivacaine, bupivacaine, and

387 lidocaine on rotator cuff tenofibroblasts. *Am J Sports Med* 42: 2888–2896.

388

389 12. Sconfienza LM, Viganò S, Martini C, et al. 2013. Double-needle ultrasound-guided

390 percutaneous treatment of rotator cuff calcific tendinitis: tips & tricks. *Skeletal Radiol* 42: 19–24.

391

392 13. Farshad M, Jundt-Ecker M, Sutter R, et al. 2012. Does subacromial injection of a local

393 anesthetic influence strength in healthy shoulders?: a double-blinded, placebo-controlled study. *J*

394 *Bone Joint Surg Am* 94: 1751–1755.

395

396 14. Coghlan JA, Forbes A, Bell SN, Buchbinder R. 2008. Efficacy and safety of a subacromial

397 continuous ropivacaine infusion for post-operative pain management following arthroscopic

398 rotator cuff surgery: A protocol for a randomised double-blind placebo-controlled trial. *BMC*

399 *Musculoskelet Disord* 9: 56.

400

- 401 15. Coghlan JA, Forbes A, McKenzie D, et al. 2009. Efficacy of subacromial ropivacaine
402 infusion for rotator cuff surgery. A randomized trial. *J Bone Joint Surg Am* 91: 1558–1567.
403
- 404 16. Gulotta LV, Kovacevic D, Packer JD, et al. 2011. Bone marrow-derived mesenchymal stem
405 cells transduced with scleraxis improve rotator cuff healing in a rat model. *Am J Sports Med* 39:
406 1282–1289.
407
- 408 17. Gulotta LV, Kovacevic D, Enteshami JR, et al. 2009. Application of bone marrow-derived
409 mesenchymal stem cell in a rotator cuff repair model. *Am J Sports Med* 37: 2126–2133.
410
- 411 18. Cohen DB, Kawamura S, Ehteshami JR, Rodeo SA. 2006. Indomethacin and celecoxib
412 impair rotator cuff tendon-to-bone healing. *Am J Sports Med* 34: 362–369.
413
- 414 19. Hettrich CM, Rodeo SA, Hannafin JA, et al. 2011. The effect of muscle paralysis using
415 Botox on the healing of tendon to bone in a rat model. *J Shoulder Elbow Surg* 20: 688–697.
416
- 417 20. Hettrich CM, Gasinu S, Beamer BS, et al. 2014. The effect of mechanical load on tendon-to-
418 bone healing in a rat model. *Am J Sports Med* 42: 1233–1241.

419

420 21. Rahnama R, Wang M, Dang AC, et al. 2013. Cytotoxicity of local anesthetics on human
421 mesenchymal stem cells. *J Bone Joint Surg Am* 95: 132–137.

422

423 22. Breu A, Rosenmeier K, Kujat R, et al. 2013. The cytotoxicity of bupivacaine, ropivacaine,
424 and mepivacaine on human chondrocytes and cartilage. *Anesth Analg* 117: 514–522.

425

426 23. Breu A, Eckl S, Zink W, et al. 2013. Cytotoxicity of local anesthetics on human
427 mesenchymal stem cells in vitro. *Arthroscopy* 29: 1676–1684.

428

429 24. Cai XY, Xiong LM, Yang SH, et al. 2014. Comparison of toxicity effects of ropivacaine,
430 bupivacaine, and lidocaine on rabbit intervertebral disc cells in vitro. *Spine J* 14: 483–490.

431

432 25. Friel NA, Wang VM, Slabaugh MA, et al. 2013. Rotator cuff healing after continuous
433 subacromioal bupivacaine infusion: an in vivo rabbit study. *J shoulder Elbow Surg* 22: 489–499.

434

435 26. Valencia Mora M, Antuna Antuna S, García Arranz M, et al. 2014. Application of adipose
436 tissue-derived stem cells in a rat rotator cuff repair model. *Injury* 45: S22–27.

437

438 27. Fox AJ, Schar MO, Wanivenhaus F, et al. 2014. Fluoroquinolones impair tendon healing in a
439 rat rotator cuff repair model: a preliminary study. *Am J Sports Med* 42: 2851–2859.

440

441 28. Kim RJ, Hah YS, Kang JR, Park HB. 2015. An antioxidant's cytoprotective effects on rotator
442 cuff tenofibroblasts exposed to aminoamide local anesthetics. *J Orthop Res* 33: 1001–1007.

443

444 29. Shirachi I, Gotoh M, Mitsui Y, et al. 2011. Collagen production at the edge of ruptured
445 rotator cuff tendon is correlated with postoperative cuff integrity. *Arthroscopy* 27: 1173–1179.

446

447 30. Gotoh M, Mitsui Y, Shibata H, et al. 2013. Increased matrix metalloprotease-3 gene
448 expression in ruptured rotator cuff tendons is associated with postoperative tendon retear. *Knee
449 Surg Sports Traumatol Arthrosc* 21: 1807–1812.

450

451 31. Hamada K, Tomonaga A, Gotoh M, et al. 1997. Intrinsic healing capacity and tearing process
452 of torn supraspinatus tendons: In situ hybridization study of $\alpha 1(I)$ procollagen mRNA. *J Orthop
453 Res* 15: 24–32.

454

455 32. Tomonaga A, Hamada K, Gotoh M, et al. 2000. Expression of procollagen $\alpha 1$ type iii mRNA
456 in rotator cuff tears. *Tokai J Exp Clin Med* 25: 125–134.

457

458 33. Aly AR, Rajasekaran S, Ashworth N. 2014. Ultrasound-guided shoulder girdle injections are
459 more accurate and more effective than landmark-guided injections: a systematic review and
460 meta-analysis. *Br J Sports Med* 49: 1042–1049.

461

462 34. Dogu B, Yucel SD, Sag SY, et al. 2012. Blind or ultrasound-guided corticosteroid injections
463 and short-term response in subacromial impingement syndrome: a randomized, double-blind,
464 prospective study. *Am J Phys Med Rehabil* 91: 658–665.

465

466 35. Yamanaka K, Fukuda H. 1991. Surgical disorders of the shoulder. In: Watson MS, editor.

467 Ageing process of the supraspinatus tendon with reference to rotator cuff tears, 1st ed. London:

468 Churchill Livingstone; p 247–258.

469

470 **Figure Legends**

471 **Figure 1**

472 Flow diagram showing how the rats were allocated into the 2 groups and into each experiment

473 LD: Lidocaine, Cont: Control, MT: Mechanical testing, Histo: Histological analysis, SEM:

474 Scanning electron microscopy

475

476 **Figure 2**

477 (a): Photograph showing the supraspinatus tendon tear made on the rat shoulder

478 (b): Scheme of the supraspinatus tendon tear

479 SSC: Subscapularis tendon, SSP: Supraspinatus tendon, ISP: Infraspinatus tendon, C: Cartilage,

480 M-T: Muscle-tendon junction

481

482 (c): Photograph showing the biomechanical testing device

483

484 **Figure 3**

485 (a): Effects of lidocaine under various concentrations (0.001%–0.1%) on cell proliferation

486 The histogram shows the mean tenocyte proliferation (%). Error bars represent the standard

487 deviation. The asterisk indicates a significant difference ($P < 0.05$).

488 (b): Effects of 0.1% lidocaine on cell viability

489 The histogram shows the mean tenocyte viability (%). Error bars represents the standard
490 deviation. The asterisk indicates a significant difference ($P < 0.05$).

491

492 **Figure 4**

493 (a): Histogram showing the mean ultimate load to failure (N)

494 Error bars represent the standard deviation. The asterisk indicates a significant difference ($P <$
495 0.05).

496 (b): Histogram showing the mean stiffness (N/mm)

497 Error bars represent the standard deviation. The asterisk indicates a significant difference ($P <$
498 0.05).

499

500 **Figure 5**

501 Picrosirius red staining at the tear site

502 (a): Photograph showing the lidocaine-exposed tear site 4 weeks after surgery

503 (b): Photograph showing the phosphate-buffered saline-exposed tear site 4 weeks after surgery

504 (Control).

505 (c): Comparison of collagen organization between the lidocaine and control groups 2, 4, and 8

506 weeks after surgery

507 Error bars represent the standard deviation. The asterisk indicates a significant difference ($P <$
508 0.05).

509

510 **Figure 6**

511 TUNEL staining at the tear site 24 h after surgery

512 (a): Lidocaine group

513 (b): Control group

514

515 **Figure 7**

516 Apoptotic cells at the tear site 24 h after surgery evaluated by scanning electron microscopy

517 (a): Lidocaine group

518 (b): Control group

519

520

521